COEPTIS THERAPEUTICS HOLDING (COEP) Stock Price, Quote, News and Overview
NASDAQ:COEP - Nasdaq - US19207A2078 - Common Stock - Currency: USD
COEP Quote, Performance and Key Statistics
NASDAQ:COEP (5/6/2025, 8:00:11 PM)
8.32
+0.22 (+2.72%)
The current stock price of COEP is 8.32 USD. In the past month the price decreased by -10.05%. In the past year, price increased by 8.56%.
COEP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.22 | 331.06B | ||
| AMGN | AMGEN INC | 13.03 | 145.40B | ||
| GILD | GILEAD SCIENCES INC | 12.65 | 121.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.6 | 60.30B | ||
| ARGX | ARGENX SE - ADR | 323.74 | 37.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.10B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.77B | ||
| NTRA | NATERA INC | N/A | 21.14B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.97B | ||
| BIIB | BIOGEN INC | 7.38 | 17.12B |
Related stock screener links
About COEP
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Company Info
COEPTIS THERAPEUTICS HOLDING
105 Bradford Road, Suite 420
Wexford PENNSYLVANIA US
Employees: 6
Phone: 17249346467
COEPTIS THERAPEUTICS HOLDING / COEP FAQ
What is the stock price of COEPTIS THERAPEUTICS HOLDING today?
The current stock price of COEP is 8.32 USD. The price increased by 2.72% in the last trading session.
What is the ticker symbol for COEPTIS THERAPEUTICS HOLDING stock?
The exchange symbol of COEPTIS THERAPEUTICS HOLDING is COEP and it is listed on the Nasdaq exchange.
On which exchange is COEP stock listed?
COEP stock is listed on the Nasdaq exchange.
What is COEPTIS THERAPEUTICS HOLDING worth?
COEPTIS THERAPEUTICS HOLDING (COEP) has a market capitalization of 28.37M USD. This makes COEP a Nano Cap stock.
How many employees does COEPTIS THERAPEUTICS HOLDING have?
COEPTIS THERAPEUTICS HOLDING (COEP) currently has 6 employees.
What are the support and resistance levels for COEPTIS THERAPEUTICS HOLDING (COEP) stock?
COEPTIS THERAPEUTICS HOLDING (COEP) has a support level at 8.11 and a resistance level at 10.05. Check the full technical report for a detailed analysis of COEP support and resistance levels.
Is COEPTIS THERAPEUTICS HOLDING (COEP) expected to grow?
The Revenue of COEPTIS THERAPEUTICS HOLDING (COEP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the COEP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy COEPTIS THERAPEUTICS HOLDING (COEP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of COEP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of COEP, evaluating the profitability, health, valuation and growth aspects
- COEPTIS THERAPEUTICS HOLDING (COEP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COEPTIS THERAPEUTICS HOLDING (COEP) Sales and EPS estimates to see what analysts future expectations are.
- COEPTIS THERAPEUTICS HOLDING (COEP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COEPTIS THERAPEUTICS HOLDING (COEP) Insider and Institutional Ownership to learn about the owners and their transactions.
- COEPTIS THERAPEUTICS HOLDING (COEP) Stock Chart to make your own analysis
- COEPTIS THERAPEUTICS HOLDING (COEP) Latest news and press-releases to stay up to date.
Does COEPTIS THERAPEUTICS HOLDING (COEP) stock pay dividends?
COEP does not pay a dividend.
What is the Price/Earnings (PE) ratio of COEPTIS THERAPEUTICS HOLDING (COEP)?
COEPTIS THERAPEUTICS HOLDING (COEP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the Short Interest ratio of COEPTIS THERAPEUTICS HOLDING (COEP) stock?
The outstanding short interest for COEPTIS THERAPEUTICS HOLDING (COEP) is 1.32% of its float. Check the ownership tab for more information on the COEP short interest.
COEP Technical Analysis
COEP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to COEP. COEP may be in some trouble as it scores bad on both profitability and health.
COEP Financial Highlights
Over the last trailing twelve months COEP reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 74.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -260.16% | ||
| ROE | -486.73% | ||
| Debt/Equity | 0.03 |
COEP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to COEP. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 98.47% and a revenue growth -100% for COEP